Tirzepatide
A synthetic dual agonist at the GIP and GLP-1 receptors — a distinct pharmacological class from selective GLP-1 agonists — developed by Eli Lilly; FDA-approved as Mounjaro (T2D, 2022) and Zepbound (weight management, 2023). Phase 3 SURPASS and SURMOUNT data demonstrate robust glycaemic control and weight reduction; SURPASS-CVOT showed non-inferiority to dulaglutide on cardiovascular events, though a standalone cardiovascular outcomes indication is not yet established. This is among the most extensively evidenced compounds on this platform.
Side effects & risks
Tirzepatide's adverse-event profile has been characterised through large Phase 3 trials in the SURPASS and SURMOUNT programmes. The following applies to the approved pharmaceutical products (Mounjaro, Zepbound). Compounded and research-chemical preparations have not undergone equivalent characterisation.
Gastrointestinal adverse events: Nausea, diarrhoea, vomiting, and constipation are the most commonly reported adverse events across all tirzepatide Phase 3 trials, consistent with the GLP-1 receptor agonist class effect. In SURMOUNT-1 (Jastreboff et al., 2022, New England Journal of Medicine; PMID 35658024), GI adverse events were reported in approximately 60-80% of tirzepatide participants versus approximately 36% placebo, with frequency dependent on dose. In SURPASS-2 (Frias et al., 2021, New England Journal of Medicine; PMID 34170647), GI adverse events in the tirzepatide arms were modestly more frequent than in the semaglutide 1 mg arm. GI events are predominantly mild to moderate, most frequent during the dose-escalation phase, and decrease in frequency over time. Approximately 4-9% of tirzepatide participants discontinued due to GI adverse events across trials versus <1-2% placebo.
Thyroid C-cell tumour risk — FDA Boxed Warning: The prescribing information for Mounjaro and Zepbound carries an FDA Boxed Warning regarding the risk of thyroid C-cell tumours, identical in mechanism and basis to the warning carried by GLP-1 receptor agonists. Rodent carcinogenicity studies demonstrated dose-dependent and duration-dependent thyroid C-cell adenomas and carcinomas. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). The human relevance of the rodent carcinogenicity finding has not been established. Patients should report neck mass, dysphagia, dysphonia, or dyspnoea.
Pancreatitis: Acute pancreatitis has been reported with tirzepatide, consistent with the GLP-1 receptor agonist class. The prescribing information recommends discontinuing tirzepatide if pancreatitis is suspected and not restarting if confirmed. A direct causal relationship has not been definitively established. Patients with a prior history of pancreatitis should discuss this risk with a clinician before initiating tirzepatide.
Hypoglycaemia: In T2D monotherapy (SURPASS-1), hypoglycaemia (blood glucose <54 mg/dL) occurred in <1% of tirzepatide participants, reflecting the glucose-dependent mechanism limiting monotherapy hypoglycaemia risk. Hypoglycaemia risk is substantially higher when tirzepatide is combined with insulin or insulin secretagogues (sulfonylureas); dose reduction of the concomitant agent is recommended when initiating tirzepatide.
Gallbladder disease: Cholelithiasis and cholecystitis have been reported with tirzepatide, consistent with the class effect shared by GLP-1 receptor agonists and attributable in part to rapid weight loss. Monitoring for gallbladder disease is recommended.
Heart rate increase: Tirzepatide produces a small increase in mean resting heart rate (approximately 2-4 beats per minute), consistent with the GLP-1 agonist class. Monitoring is appropriate.
Injection-site reactions: Local reactions (redness, swelling, pain) occur with subcutaneous injection at low frequency and are generally mild. Rotating injection sites is recommended.
Hypersensitivity: Hypersensitivity reactions including rash and urticaria, and in rare cases angioedema or anaphylaxis, have been reported. Patients should seek immediate medical care for serious hypersensitivity symptoms.
Acute kidney injury: Acute kidney injury — associated with dehydration from GI adverse events — has been reported. Maintaining adequate hydration, especially during GI illness, is important.
Tirzepatide is a prescription drug. The benefit-risk characterisation applies to the approved pharmaceuticals (Mounjaro, Zepbound). Compounded and research-chemical preparations have not been evaluated under equivalent conditions.
Evidence summary
Latest studies
Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database network.
The European Sleep Apnoea Database network surveyed 24 sleep centres across 14 countries about how they are using GLP-1 receptor agonists in patients with obesity and obstructive sleep apnoea. Practice varies widely: 42% of centres allow sleep physicians to start these drugs in the sleep clinic, most still order sleep studies after initiation, a majority regard more than 10% weight loss as the threshold for reassessment, and only 14% proactively revisit CPAP settings. The paper reports clinician practice, not patient outcomes.
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study.
This study used an improved computer model to estimate whether tirzepatide is good value for money compared with diet and exercise alone for treating obesity in the UK. It fed in results from the SURMOUNT trials and added more realistic modelling of how type 2 diabetes and sleep apnoea change over time. The model concluded that all doses of tirzepatide would be considered cost-effective under the UK's usual value-for-money threshold. Much of the paper is about technical upgrades to how the model works rather than new medical results. Because it reuses existing trial data and does not tell us anything new about how well tirzepatide works or how safe it is, we are holding it from the studies feed. It is mainly useful for health-system funding decisions.
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
This study compared the cost of two diabetes medicines, tirzepatide and semaglutide, in the UK, specifically, how much you would spend per patient who reaches certain treatment goals combining blood-sugar control and weight loss. It used the proportions of patients hitting those goals from an earlier trial (SURPASS-2) and combined them with UK drug prices. For most of the tougher goals, tirzepatide cost less per patient who reached the target. This is a cost calculation, not a new medical study; it does not tell us anything new about how well the drugs work or how safe they are, only about their value for money under UK pricing. Because it adds no new clinical findings about the medicines, we are holding it from the studies feed; it is mainly of interest to health-system budget planners.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“To anyone who is using Reta and Tirz”
A user solicits experiences from people running retatrutide and tirzepatide together, reflecting community interest in combining or transitioning between the two incretin agents; the thread is a question to peers, with no comments pulled to capture responses.
“Has anyone here used tirzepatide together with CJC-1295 DAC?”
A user asks whether others have combined tirzepatide with CJC-1295 DAC, soliciting community experience on running a GLP-1/GIP agonist alongside a growth-hormone-releasing-hormone analog in the same protocol.
“Mounjaro or RETZ”
A user-profile post asking whether to choose Mounjaro (tirzepatide) or retatrutide, a comparison question commonly raised by people deciding between the two incretin-based compounds.
“37M: Before vs now, starting TRT soon. Tirzepatide or retatrutide for abdominal/visceral fat while preserving muscle?”
A 37-year-old man shares a before-and-now progress post, notes he is about to start TRT, and asks whether tirzepatide or retatrutide is the better fit for reducing abdominal and visceral fat while preserving muscle.
“37M: Before vs now, starting TRT soon. Tirzepatide or retatrutide for abdominal/visceral fat while preserving muscle?”
A 37-year-old man sharing progress photos and about to start testosterone therapy asks whether tirzepatide or retatrutide is the better fit for targeting abdominal and visceral fat while keeping muscle mass. The thread compares the two incretin agonists for body-composition goals.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Type 2 diabetes (Mounjaro, FDA-approved) | SC injection (abdomen, thigh, or upper arm) | 2.5 mg -> 5 mg -> 7.5 mg -> 10 mg -> 12.5 mg -> 15 mg | Once weekly | Minimum 4 weeks at each dose before escalating; 5-15 mg is therapeutic range per prescribing information |
| Chronic weight management (Zepbound, FDA-approved) | SC injection (abdomen, thigh, or upper arm) | 2.5 mg -> 5 mg -> 7.5 mg -> 10 mg -> 12.5 mg -> 15 mg (typical maintenance 10-15 mg) | Once weekly | Minimum 4 weeks at each dose before escalating; concurrent lifestyle modification (reduced-calorie diet and increased physical activity) required per prescribing information |
Frequently asked questions
- What is tirzepatide approved for?
- Tirzepatide is FDA-approved in two formulations: Mounjaro (subcutaneous injection, May 2022) for type 2 diabetes mellitus in adults and pediatric patients ≥10 years; and Zepbound (subcutaneous injection, November 2023) for chronic weight management in adults with BMI >=30 kg/m2, or >=27 kg/m2 with at least one weight-related comorbidity. Both require a prescription. Tirzepatide does not hold an FDA cardiovascular outcomes indication in current prescribing information (label effective 2026-04-22). SURPASS-CVOT primary results have been published (Nicholls SJ et al., 2025, N Engl J Med; PMID 41406444); the trial demonstrated non-inferiority to dulaglutide (an active GLP-1 comparator with its own established CV benefit) for 3-point MACE — an active-comparator non-inferiority result, not a placebo-controlled superiority finding.
- How much weight does tirzepatide produce in clinical trials?
- Clinical trial results describe population averages and should not be interpreted as individual predictions. In SURMOUNT-1 (Jastreboff et al., 2022, New England Journal of Medicine; PMID 35658024), adults with obesity or overweight without type 2 diabetes treated with tirzepatide 15 mg weekly for 72 weeks lost a mean of 20.9% of initial body weight versus 3.1% placebo; 57% achieved >=20% weight loss. Mean losses for 5 mg and 10 mg were 15.0% and 19.5% respectively. In SURMOUNT-2 (Garvey et al., 2023, Lancet; PMID 37385275), adults with type 2 diabetes and obesity lost a mean of 12.8% (10 mg) and 14.7% (15 mg) versus 3.2% placebo.
- Is tirzepatide better than semaglutide?
- Direct comparisons require careful framing. In SURPASS-2 (Frias et al., 2021, New England Journal of Medicine; PMID 34170647), tirzepatide at all tested doses (5, 10, and 15 mg weekly) produced statistically superior HbA1c reductions and greater weight loss than semaglutide 1 mg weekly in T2D patients — with the important caveat that semaglutide 2 mg was not included. No published Phase 3 trial has directly compared tirzepatide to high-dose semaglutide 2.4 mg for weight management. Additionally, tirzepatide does not yet hold an approved cardiovascular outcomes indication, whereas semaglutide holds such an indication in both T2D (SUSTAIN-6, PMID 27633186) and obesity without T2D (SELECT, PMID 37952131).
- What are the most serious risks of tirzepatide?
- The FDA Boxed Warning on Mounjaro and Zepbound prescribing information concerns the risk of thyroid C-cell tumours, observed in rodent carcinogenicity studies; the human relevance is unknown but cannot be excluded. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Additional serious adverse events include acute pancreatitis, gallbladder disease, and — when combined with insulin or sulfonylureas — hypoglycaemia. GI adverse events (nausea, diarrhoea, vomiting) are the most commonly reported events and are typically mild to moderate.
- How does tirzepatide's dual GIP/GLP-1 mechanism differ from semaglutide's single GLP-1 mechanism?
- Semaglutide activates only the GLP-1 receptor (GLP-1R), which drives glucose-dependent insulin secretion, glucagon suppression, appetite reduction, and gastric emptying delay. Tirzepatide activates both GLP-1R and the GIP receptor (GIPR) simultaneously. GIP-R activation at pancreatic beta cells provides additional insulin secretion stimulation via distinct intracellular pathways; GIP-R is also expressed in adipose tissue and neuronal circuits where its role in metabolic regulation is an active area of research. The superiority of tirzepatide over semaglutide 1 mg in SURPASS-2 (PMID 34170647) for both HbA1c and body weight suggests the dual mechanism provides additive efficacy, though the precise molecular basis for this additive effect at the whole-organism level has not been fully resolved.